Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.

Li J, Wu Y, Wang D, Zou L, Fu C, Zhang J, Leung GP.

Pharmacol Res. 2019 Jun 13;146:104313. doi: 10.1016/j.phrs.2019.104313. [Epub ahead of print]

PMID:
31202781
2.

Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells.

Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M, Wang Y.

Am J Chin Med. 2013;41(1):177-96. doi: 10.1142/S0192415X13500134.

PMID:
23336515
3.

pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.

Zhang J, Li J, Shi Z, Yang Y, Xie X, Lee SM, Wang Y, Leong KW, Chen M.

Acta Biomater. 2017 Aug;58:349-364. doi: 10.1016/j.actbio.2017.04.029. Epub 2017 Apr 26.

PMID:
28455219
4.

Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.

Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS.

Biochim Biophys Acta. 2014 Jan;1840(1):615-25. doi: 10.1016/j.bbagen.2013.10.023. Epub 2013 Oct 24.

PMID:
24161697
5.

A novel compound DT-010 protects against doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by inhibiting reactive oxygen species-mediated apoptotic and autophagic pathways.

Tang F, Zhou X, Wang L, Shan L, Li C, Zhou H, Lee SM, Hoi MP.

Eur J Pharmacol. 2018 Feb 5;820:86-96. doi: 10.1016/j.ejphar.2017.12.021. Epub 2017 Dec 9.

PMID:
29229534
6.

Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.

Jo A, Choi TG, Jo YH, Jyothi KR, Nguyen MN, Kim JH, Lim S, Shahid M, Akter S, Lee S, Lee KH, Kim W, Cho H, Lee J, Shokat KM, Yoon KS, Kang I, Ha J, Kim SS.

Antioxid Redox Signal. 2017 Jan 10;26(2):70-83. doi: 10.1089/ars.2015.6457. Epub 2016 Aug 5.

PMID:
27357096
7.

Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways.

Li J, Bao L, Zha D, Zhang L, Gao P, Zhang J, Wu X.

Int Immunopharmacol. 2018 Feb;55:9-19. doi: 10.1016/j.intimp.2017.11.040. Epub 2017 Dec 5.

PMID:
29207360
8.

Beet root juice protects against doxorubicin toxicity in cardiomyocytes while enhancing apoptosis in breast cancer cells.

Das S, Filippone SM, Williams DS, Das A, Kukreja RC.

Mol Cell Biochem. 2016 Oct;421(1-2):89-101. doi: 10.1007/s11010-016-2789-8. Epub 2016 Aug 26.

PMID:
27565811
9.

Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight.

Rai G, Mishra S, Suman S, Shukla Y.

Phytomedicine. 2016 Mar 15;23(3):233-42. doi: 10.1016/j.phymed.2015.12.020. Epub 2016 Jan 27.

PMID:
26969377
10.

The effects of β-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice.

Hanušová V, Caltová K, Svobodová H, Ambrož M, Skarka A, Murínová N, Králová V, Tomšík P, Skálová L.

Biomed Pharmacother. 2017 Nov;95:828-836. doi: 10.1016/j.biopha.2017.09.008. Epub 2017 Sep 10.

PMID:
28903178
11.

GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.

Pi J, Jiang J, Cai H, Yang F, Jin H, Yang P, Cai J, Chen ZW.

Drug Deliv. 2017 Nov;24(1):1549-1564. doi: 10.1080/10717544.2017.1386729.

PMID:
29019267
12.
13.

Anticancer effects of oridonin on colon cancer are mediated via BMP7/p38 MAPK/p53 signaling.

Liu RX, Ma Y, Hu XL, Ren WY, Liao YP, Wang H, Zhu JH, Wu K, He BC, Sun WJ.

Int J Oncol. 2018 Nov;53(5):2091-2101. doi: 10.3892/ijo.2018.4527. Epub 2018 Aug 16.

PMID:
30132514
14.

Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.

Gunasekaran VP, Nishi K, Sivakumar D, Sivaraman T, Mathan G.

Eur J Pharm Sci. 2018 Apr 30;116:2-14. doi: 10.1016/j.ejps.2017.09.019. Epub 2017 Sep 12.

PMID:
28916481
15.

Molecular mechanisms of apoptosis and autophagy elicited by combined treatment with oridonin and cetuximab in laryngeal squamous cell carcinoma.

Cao S, Huang Y, Zhang Q, Lu F, Donkor PO, Zhu Y, Qiu F, Kang N.

Apoptosis. 2019 Feb;24(1-2):33-45. doi: 10.1007/s10495-018-1497-0.

PMID:
30430397
16.

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.

PMID:
18695136
17.

Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells.

Sharma G, Tyagi AK, Singh RP, Chan DC, Agarwal R.

Breast Cancer Res Treat. 2004 May;85(1):1-12.

PMID:
15039593
18.

β-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB2) receptors in rats.

Meeran MFN, Al Taee H, Azimullah S, Tariq S, Adeghate E, Ojha S.

Chem Biol Interact. 2019 May 1;304:158-167. doi: 10.1016/j.cbi.2019.02.028. Epub 2019 Mar 2.

PMID:
30836069
19.

The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line.

Elsherbiny NM, Younis NN, Shaheen MA, Elseweidy MM.

Pathol Res Pract. 2016 Sep;212(9):767-77. doi: 10.1016/j.prp.2016.06.004. Epub 2016 Jun 22.

PMID:
27493101
20.

Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway.

Cao S, Xia M, Mao Y, Zhang Q, Donkor PO, Qiu F, Kang N.

Int J Oncol. 2016 Nov;49(5):2075-2087. doi: 10.3892/ijo.2016.3696. Epub 2016 Sep 19.

PMID:
27667173

Supplemental Content

Support Center